Pharmacotherapy of attention deficit hyperactivity disorder in children: the results of a multicenter double-blind placebo-controlled study of hopantenic acid

Abstract

There was a trend towards an increase in the percentage of patients with positive changes (a decrease in the total ADHD-DSM-IV by ≥25%) in the end of the 3rd and 4th month in the pantogam group (treatment response was 66.7 and 68.9%, respectively) compared to the placebo group (treatment response was 52.3 and 61.4%, respectively). A significant decrease in disease severity assessed by the CGI-S was noted in the pantogam group compared to the placebo group. After 4 month of treatment with pantogam, the severity of functional disturbances was reduced by 4 out of 6 WFIRS-P domains: Family, School and learning, Child's self-concept and Risky activities. Pantogam improved the measures of sustained attention (accuracy and speed) in the Toulouse-Piéron test. The drug used in mean daily dose 30 mg/kg during 4 month had a favorable safety profile which did not differ from that of placebo.

Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)

“…Reboxetine is a specific NRI [33] suggested as potentially useful for attention and executive functions [34]. Reboxetine was tested in adults [35] and children [36] with suggestions of partial efficacy and with adverse effects including headache, low appetite, sleep disturbances, anxiety and irritability.…”

“…Its involvement with attention or ADHD is not clearly based. NPG was studied [33] on 6 children with ADHD without comorbidity. In this double-blind randomized controlled trial against placebo, NPG was titrated over 4 months up to 30 mg/kg in two daily fractions.…”